

WO 2025/157271 PCT/CN2025/074764

[图 1]





细则 91,
24.02.2025


[图 2]




[图 3]


Relative F11 mRNA
1.0
0.8
0.6
0.4
0.2
0.0
E3
E4
E5
E6
E8
E9
E13
E14
E15
E16
E18
E19
E20
E24
E26
E50
E51
E52
E53
E54
E55
E56
E68
E69
E70
E82
ERB2
ERB4
ERB6
ERB7
ETJ632
ETJ645
ETJ772
ISIS-416858


[图 4]


Relative F11 mRNA
1.0
0.8
0.6
0.4
0.2
0.0
-6
-4
-2
0
2
4
Log (nM)
GE14
GE19
GE26
GE50
E70
E82


[图 5]


Relative FXI level (%)
120
100
80
60
40
20
0
-3
7
13
20
27
34
41
55
62
Days
BLANK
GE50
GE70
GE82
GE14
GE24
GE3
GE26
GE15
GE19
GE8


[图 6]


Relative FXI level to pre-dose(%)
LN50-E05
GN50-E05
-3
7
14
28
42
56
Days
LN26-E05
GN26-E05
33
70

[图 7]


Relative FXI mRNA
1.0
0.8
0.6
0.4
0.2
0.0
-6
-4
-2
0
2
4
Log (nM)
GN26-E05
GN26-E05VP
GN50-E05
GN50-E05VP

[图 8]


120
80
40
20
0
Relative FXI level (%)
-1
7
14
21
28
Days
GN50E04VP
GN50E05
GN50E20VP
GN50E05VP